Volume 3, Issue 6, November 2015, Page: 137-142
Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer
Ashraf Anas Zytoon, Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Eman Abdel Razek Tawfek, Nuclear Medicine & Clinical Oncology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Adel Mohamed Elwakil, Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Gilan Ibrahim Aladle, Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Received: Oct. 31, 2015;       Accepted: Nov. 10, 2015;       Published: Nov. 26, 2015
DOI: 10.11648/j.ijmi.20150306.15      View  3914      Downloads  91
Abstract
Prostate cancer (PCa) represents the most common non-cutaneous malignancy for men, where an estimated 241,740 new cases will be diagnosed in 2013 in the United States [1]. Whereas most of those new diagnoses will be clinically localized, up to 17% of patients may experience metastatic disease, in which the risk of cancer- specific mortality is increased [2]. In this context, it is well established that, beyond regional lymph nodes, the skeleton represents the most common metastatic site [3].The study aims to evaluate the pattern of distribution of bone metastases in prostate cancer patients by 99mTc- methylene diphosphonate (99mTc-MDP) bone scintigraphy. It was formed in 150 patients with pathologically proven prostate cancer and presented for bone scans with 99mTc-methylene diphosphonate (99mTc-MDP) for detection and evaluation of bone metastases. It was noted that patients with bone metastases had significantly higher frequency of bone pain when compared with patients without and noted that spine was the most commonly affected site (60.0 %) followed by ribs (52.0 %) and femur (30.0 %). Spread of bony metastases among the bony skeleton has distribution manner not only to the right or to the left. Metastatic bony lesions of prostate cancer are located mainly in spine (58.0%) followed by ribs (52.0 %) and femur (30.0 %). Patients with extensive bone metastasis had significantly higher frequency of skull, spine, scapula, humerous, sternum, ribs, iliac bone, ischium, and femur metastases
Keywords
Prostate Cancer, Bone Scan, Bone Metastases, MDP
To cite this article
Ashraf Anas Zytoon, Eman Abdel Razek Tawfek, Adel Mohamed Elwakil, Gilan Ibrahim Aladle, Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer, International Journal of Medical Imaging. Vol. 3, No. 6, 2015, pp. 137-142. doi: 10.11648/j.ijmi.20150306.15
Copyright
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013; 63(1): 11–30.
[2]
Scosyrev E, Messing EM, Mohile S, et al. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118(12): 3062–3070.
[3]
Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106(7): 1624–1633.
[4]
Russel P.J, P.Jackson,E.A. Kingsley. Prostate cancer methods and protocols. Methods in Molecular Medicine.2003; 81: 1-19.
[5]
Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ.2010; 341: c4543.
[6]
Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide. IARC Cancer Base No. 10.Int Agency Res Canc 2010.
[7]
Freddy S, Max P, Zvavahera C, et al. Cancers. In Disease and Mortality in Sub-Saharan Africa. World Bank; 2006.
[8]
Danley KL, Richardson JL, Bernstein L, et al. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States).Cancer Causes Control 1995; 6(6): 492-498.
[9]
Vinjamoori AH, Jagannathan JP, Shinagare AB, et al. A typical metastases from prostate cancer: 10-year experience at a single institution. Am J Roentgenol 2012; 199(2): 367-372.
[10]
Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer.Eur Urol 2006; 49(3): 429-440.
[11]
Rajendiran G, Green L, Chhabra G. A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. Int J Case Rep Image 2011; 2(9): 16-20.
[12]
Migita T, Maeda K, Ogata N. A case of prostate cancer associated with osteolytic bone metastases.Hinyokika Kiyo 1999; 45(5): 371-374.
[13]
Lin K, Szabo Z, Chin BB, Civelek AC. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med. 1999; 24: 579–582.
[14]
Conti G, La Torre G, Cicalese V, et al. Prostate cancer metastases to bone: Observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the metauro protocol and of patient baseline features. Arch Ital Urol Androl. 2008; 80: 59–64.
[15]
Maffioli L, Florimonte L, Pagani L, et al. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004; 31(Suppl 1): S143–S148.
[16]
Wang CY, Wu GY, Shen MJ, et al. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol Lett. 2013 Jan; 5(1): 391-397.
[17]
Scher B, Seitz M, Albinger W, et al. Value of PET and PET/CT in the diagnostics of prostate and penile cancer. Recent Results Cancer Res. 2008; 170: 159-79.
[18]
Levren G, Sadik M, Gjertsson P, et al. Relation between pain and skeletal metastasis in patients with prostate or breast cancer. Clin Physiol Funct Imaging. 2011 May; 31(3): 193-5.
[19]
Helyar V, Mohan HK, Barwick T, et al: The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010; 37: 706–713.
[20]
Elabbady A, Eid A, Fahmy A, et al. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol. 2014; 67(4): 351-6.
[21]
Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008 Nov; 10(6): 890-5.
[22]
Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014 Feb; 74(2): 210-6.
[23]
Kakhki VR, Anvari K, Sadeghi R, et al. Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013; 16(2): 66-9.
Browse journals by subject